Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Modular switchgear built for faster, verified panel builds
As switchboard builders face tighter programmes and increasing scrutiny around compliance, the way enclosure, busbar and separation concepts work together has a direct impact on build time and verification effort.
